0.36
price down icon4.38%   -0.0165
pre-market  Pre-market:  .39   0.03   +8.33%
loading
Entero Therapeutics Inc stock is traded at $0.36, with a volume of 129.71K. It is down -4.38% in the last 24 hours and down -34.89% over the past month. Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.3765
Open:
$0.3652
24h Volume:
129.71K
Relative Volume:
0.22
Market Cap:
$1.69M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.81%
1M Performance:
-34.89%
6M Performance:
-42.93%
1Y Performance:
+0.00%
1-Day Range:
Value
$0.3404
$0.37
1-Week Range:
Value
$0.3307
$0.3899
52-Week Range:
Value
$0.185
$3.00

Entero Therapeutics Inc Stock (ENTO) Company Profile

Name
Name
Entero Therapeutics Inc
Name
Phone
561-589-7020
Name
Address
777 YAMATO ROAD, BOCA RATON
Name
Employee
2
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
ENTO's Discussions on Twitter

Compare ENTO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ENTO
Entero Therapeutics Inc
0.36 1.69M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Entero Therapeutics Inc Stock (ENTO) Latest News

pulisher
Apr 22, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Apr 22, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 14, 2025

Entero Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Entero Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Apr 14, 2025
pulisher
Apr 09, 2025

Titan Environmental Solutions Inc. Appoints Edward J. Borkowski and Edward F. Feighan to its Board of Directors - The Manila Times

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 07, 2025
pulisher
Apr 04, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Apr 03, 2025
pulisher
Apr 02, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Entero Therapeutics Delays 10-K Filing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com

Apr 01, 2025
pulisher
Mar 25, 2025

Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN

Mar 25, 2025
pulisher
Mar 24, 2025

Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail

Mar 21, 2025
pulisher
Mar 21, 2025

Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail

Mar 21, 2025
pulisher
Mar 21, 2025

Hogs Close with Weakness on Thursday - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail

Mar 20, 2025
pulisher
Mar 20, 2025

This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail

Mar 20, 2025
pulisher
Mar 19, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail

Mar 19, 2025
pulisher
Mar 18, 2025

European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail

Mar 18, 2025
pulisher
Mar 18, 2025

The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail

Mar 18, 2025
pulisher
Mar 17, 2025

Celiac Disease Market Expected to Experience Major Growth - openPR

Mar 17, 2025
pulisher
Mar 17, 2025

Significant Contract News Sends Energy Services Company Higher - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag

Mar 17, 2025
pulisher
Mar 15, 2025

3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail

Mar 15, 2025
pulisher
Mar 14, 2025

Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive

Mar 14, 2025
pulisher
Mar 14, 2025

Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail

Mar 14, 2025
pulisher
Mar 13, 2025

Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz

Mar 13, 2025
pulisher
Mar 13, 2025

Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire

Mar 13, 2025
pulisher
Mar 12, 2025

3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail

Mar 12, 2025
pulisher
Mar 11, 2025

Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail

Mar 11, 2025
pulisher
Mar 10, 2025

Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail

Mar 10, 2025
pulisher
Mar 05, 2025

Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail

Mar 05, 2025
pulisher
Mar 04, 2025

Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail

Mar 04, 2025
pulisher
Mar 03, 2025

Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - The Business Journals

Mar 03, 2025
pulisher
Feb 28, 2025

Onconetix names new executive chairman, appoints board member - Investing.com

Feb 28, 2025
pulisher
Feb 26, 2025

iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Feb 26, 2025
pulisher
Feb 17, 2025

Entero Therapeutics Appoints Richard Paolone as CEO - citybiz

Feb 17, 2025
pulisher
Feb 16, 2025

AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com

Feb 16, 2025
pulisher
Feb 15, 2025

Entero Therapeutics names Richard Paolone interim CEO - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa

Feb 14, 2025
pulisher
Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch

Feb 14, 2025
pulisher
Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com

Feb 14, 2025

Entero Therapeutics Inc Stock (ENTO) Financials Data

There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):